FLF

The Future Landscapes Forum: Scientists and practitioners criticise 'dangerous' attempts to ban controlled burning on heather moors

Retrieved on: 
Wednesday, August 30, 2023
Wildfire, Associate, Policy, University of York, Biodiversity, Communication, University, Research, FLF, Risk, Carbon, Hunting

The group says these decisions disregard a large body of evidence showing that controlled burning can support wildfire prevention, carbon capture, and biodiversity improvement.

Key Points: 
  • The group says these decisions disregard a large body of evidence showing that controlled burning can support wildfire prevention, carbon capture, and biodiversity improvement.
  • Moreover, risks and impacts of alternatives like cutting or no vegetation management remain largely unknown and are often ignored.
  • We support regulations that steer practitioners towards good standards of controlled burning and encourage better communication links between policymakers and those leading research into the management of the UK's heather-dominated landscapes," Heinemeyer added.
  • Frankly, we would be making the case for controlled burning if grouse, and grouse shooting, did not exist.

New funding of $2 million for research bringing us one step closer to a cure for Follicular Lymphoma

Retrieved on: 
Tuesday, November 29, 2022
Oncology, Health, Stem Cells, Clinical Trials, General Health, Pharmaceutical, Bangladesh Technical Education Board, CSP, Non-Hodgkin lymphoma, Patient, Lymphatic system, CURE, Drug development, Research, Milken Institute, FLF, Clinical trial, Follicular lymphoma, Pharmaceutical industry, Medical device

The grants have been made through the Foundations CURE FL Awards programme to support targeted and innovative research projects.

Key Points: 
  • The grants have been made through the Foundations CURE FL Awards programme to support targeted and innovative research projects.
  • With this funding programme, we are putting this disease front and centre in Lymphoma research, and catalysing the development of therapies for the underserved patient populations.
  • Nicky Greenhalgh, Founder of the Living with Follicular Lymphoma community and Patient Representative on the Awards review panel) said: The CURE FL Awards mean real progress towards a cure.
  • The FLF worked closely with its partners, the Centre for Strategic Philanthropy (CSP) at the Milken Institute, to develop the CURE FL Awards programme.

CNL and First Light Fusion Partner to Explore Tritium Extraction Technologies

Retrieved on: 
Monday, November 28, 2022
Lithium, Hydrogen, Tritium, Atomic Energy of Canada Limited, Waste management, Environment, History, United Kingdom, CNRI, Engineering, Helium, University, Private sector, Vision 2030, First Light, Climate change, Science, Government, Optimism, National Nuclear Laboratory, Electricity, SMR, Health, FLF, AR, AECL, Safety, CNL, Renewable energy, Medicine

CNL is thrilled to enter into this project with First Light Fusion, a company that shares our ambition and commitment to the pursuit of next-generation clean energy technologies, commented Dr. Jeff Griffin, CNLs Vice-President of Science & Technology.

Key Points: 
  • CNL is thrilled to enter into this project with First Light Fusion, a company that shares our ambition and commitment to the pursuit of next-generation clean energy technologies, commented Dr. Jeff Griffin, CNLs Vice-President of Science & Technology.
  • Our design will allow tritium self-sufficiency, and CNL will support us with the initial design of a system capable of extracting tritium.
  • Ultimately, the need for fusion is urgent, which is why we are working to solve fusion with the simplest machine possible.
  • The tritium extraction system represents an essential part of tritium control in a fusion fuel cycle, and is a key factor in harvesting the tritium and limiting tritium permeation into the coolant.

ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028

Retrieved on: 
Monday, July 18, 2022
San Francisco, SEC, University, Patient, Security (finance), Surgeon, Safety, U.S. Securities and Exchange Commission, Visual acuity, CAGR, Stanford University, GLOBE, Retinitis pigmentosa, Forward-looking statement, Technology, Diabetic retinopathy, Ophthalmology, Risk, CNS, Severe cognitive impairment, Retina, University of California, San Francisco, NASDAQ, Eye, Company, CGMP, PBS, Growth, Macular degeneration, Cedars-Sinai Medical Center, Prevalence, ADH, CA, Retinal, SOC, USD, Patient-reported outcome, Suction, FLF, Sulfur hexafluoride, Adipic acid dihydrazide, Medical device, Dentistry, Pharmaceutical industry

FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, according to a recent study by Bosson Research, the global Retinal Surgical Instruments market, valued at USD 1.59 billion in 2021, is expected to reach USD2.46 billion by the end of 2028, growing at a CAGR of 6.08% between 2022 and 2028.  This growth is expected to benefit ABVC’s development of its medical device, Vitargus, a gel-like substance that aims to help the eye maintain a round shape and keep the retina in place during and after retina re-attachment surgery.

Key Points: 
  • Growing instances of retinal disorders in the geriatric population, eye injuries and rising prevalence of diabetic retinopathy are the key driving factors in the retinal surgery devices market.
  • ABVCs Vitargus is a medical device intended to solve an important issue faced by surgeons following retinal re-attachment, namely patient comfort.
  • This allows for a variety of repairs, including the removal of scar tissue, laser repair of retinal detachments and treatment of macular holes.
  • Global Retinal Surgery Devices Market Research Report 2022 (Status and Outlook).

ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process

Retrieved on: 
Thursday, May 5, 2022
U.S. Securities and Exchange Commission, Forward-looking statement, University, University of California, San Francisco, Cedars-Sinai Medical Center, FLF, NASDAQ, GLOBE, CNS, Company, Retina, Safety, CA, San Francisco, CGMP, Patient, Security (finance), Risk, Ophthalmology, Visual acuity, SEC, Technology, Stanford University, Medical device, Pharmaceutical industry

Fremont, CA, May 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, its gel-like substance that helps the eye maintain a round shape and keeps the retina in place during and after retinal re-attachment surgery, will be manufactured through a new aseptic process that enhances the stability, consistency and efficacy of the final product, while significantly reducing manufacturing time. This new manufacturing process eliminates the labor-intensive and time-consuming gamma ray sterilization of the Vitargus components by using a sterile fill-lyophilization-finish (FLF). 

Key Points: 
  • This new manufacturing process eliminates the labor-intensive and time-consuming gamma ray sterilization of the Vitargus components by using a sterile fill-lyophilization-finish (FLF).
  • We are pleased to have an innovative and experienced R&D team dedicated to developing new manufacturing technologies for Vitargus that improve quality and reduce manufacturing cost, said Dr. Howard Doong, Chief Executive Officer of ABVC.
  • With this new process, we can easily transform Vitargus to a high-volume commercial product.
  • The new streamlined manufacturing process has been successfully scaled up under cGMP conditions to ensure enough Vitargus can be economically produced for both Phase II, as well as subsequent Phase III clinical studies involving more than 175 patients.

FATTY LIVER FOUNDATION launches THE STATE OF NAFLD/NASH CARE IN AMERICA™ initiative to support improved patient care

Retrieved on: 
Monday, April 18, 2022
CEO, Awareness, Liver disease, Behavior, FLF, Population, Fatty liver disease, Diagnosis, NASH, Entrepreneurship, YouTube, Education, Chronic liver disease, Patient, Mortality, Mental health, Hepatitis, HRQOL, NEWS, Solution, NAFLD, Non-alcoholic fatty liver disease, Steatosis, Scar, Cirrhosis, Liver failure, Health insurance, Dietary supplement, Medical imaging, Twitter, Facebook

BOISE, Idaho, April 18, 2022 /PRNewswire-PRWeb/ -- The Fatty Liver Foundation (FLF) today announced the launch of The State of NAFLD/NASH Care in America™, a first-of-its-kind national initiative that aims to make a big impact within the NAFLD/NASH community by surveying the lived experiences of adults with NAFLD/NASH in the United States and fostering the continuous development and integration of actionable solutions to improve the diagnosis, treatment, care, and support for people with NAFLD/NASH.

Key Points: 
  • Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide.
  • It is characterized by steatosis or infiltration of liver cells with fat, liver inflammation, liver cells injury, and progressive fibrosis.
  • The Fatty Liver Foundation is a non-profit patient organization dedicated to improving the identification, diagnosis, treatment and support of people living with fatty liver, NAFLD or NASH through awareness, screening, education, and patient outreach.
  • Connect with us on http://www.fattyliverfoundation.org , Facebook (Fatty Liver Foundation JUST LIVER NEWS), Twitter (@LiverSaver), and YouTube (Fatty Liver Foundation).

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Monday, October 4, 2021
ELF, Mortality, Health, Elastography, Icahn School of Medicine at Mount Sinai, Private Securities Litigation Reform Act, Non-alcoholic fatty liver disease, Communication, Entrepreneurship, Judgement, Cirrhosis, Safety, Industry, SEC, Institute of Liver and Biliary Sciences, Liver, U.S. Securities and Exchange Commission, Mount Sinai, Association, NAFLD, CEO, Knowledge, Awareness, Disease, Incidence, Fatty liver disease, Liver disease, Clinical trial, Partnership, American Association of Clinical Endocrinologists, Achievement, Risk, Annual report, Therapy, NASDAQ, FDA, Cancer, Investor, Accelerated approval (FDA), FLF, Forward-looking statement, Fibrosis, Time, Education, GLOBE, THR, MRE, American Association, Diagnosis, Patient, Fund, Ownership, Research, Nasdaq, Dietary supplement, Pharmaceutical industry, Medical imaging

Today, Madrigal and the Fatty Liver Foundation will ring the Nasdaq closing bell to raise awareness of the need for more evidence-based screening and testing to improve diagnosis and staging of NAFLD/NASH.

Key Points: 
  • Today, Madrigal and the Fatty Liver Foundation will ring the Nasdaq closing bell to raise awareness of the need for more evidence-based screening and testing to improve diagnosis and staging of NAFLD/NASH.
  • NASH is known as a silent disease because many people dont know they have it until it has progressed to a dangerous stage.
  • Madrigal is providing an unrestricted grant to support FLFs NAFLD Screening Fund whose primary objective is to scale-up evidence-based screening and testing for NAFLD in a community setting.
  • These efforts would support, and potentially boost, the non-invasive screening needed to identify asymptomatic disease and diagnosing NAFLD/NASH patients at various points of progression.

2018 Future Leaders Forum to Showcase Hottest Trends in Leadership

Retrieved on: 
Thursday, July 12, 2018
Piscataway, New Jersey, Institute of Electrical and Electronics Engineers, FLF

WASHINGTON, July 12,2018 /PRNewswire-USNewswire/ --The hottest trends in leadership and technology will be on center stage at the 2018 Future Leaders Forum , presented by IEEE-USA .

Key Points: 
  • WASHINGTON, July 12,2018 /PRNewswire-USNewswire/ --The hottest trends in leadership and technology will be on center stage at the 2018 Future Leaders Forum , presented by IEEE-USA .
  • Hundreds of young and mid-career professionals are expected to descend on Austin, Texas, for this one-of-a-kind event from July 26-28, 2018.
  • The forum will offer insightful and thoughtful content, fun and interactive activities and more than 30 exciting speakers to promote discussions on the issues that matter most to today's workforce.
  • "With several sessions focused on leadership in each track, trendsetting speakers, and networking opportunities galore, there is no better place to find inspiration than FLF 2018."